Eledon Pharmaceuticals (ELDN) Other Non-Current Liabilities (2015 - 2026)

Eledon Pharmaceuticals (ELDN) has 6 years of Other Non-Current Liabilities data on file, last reported at $30.4 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 12.72% year-over-year to $30.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.4 million (down 12.72% YoY) and the FY2025 annual result came in at $11.4 million, down 74.55% from the prior year.
• Other Non-Current Liabilities advanced to $30.4 million in Q1 2026, from $11.4 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $120.8 million in Q2 2024 to a low of $11.4 million in Q4 2025.
• A 4-year average of $49.0 million and a median of $39.8 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities surged 115.06% — and 2025, when it tumbled 81.37%.
• Tracing ELDN's Other Non-Current Liabilities over 4 years: stood at $76.2 million in 2023, then sank by 41.13% to $44.9 million in 2024, then sank by 74.55% to $11.4 million in 2025, then surged by 166.1% to $30.4 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $30.4 million (Q1 2026), $11.4 million (Q4 2025), and $21.9 million (Q3 2025), per Business Quant data.